Format

Send to

Choose Destination
Med Care. 2014 Mar;52 Suppl 3:S132-9. doi: 10.1097/MLR.0b013e3182a53ca8.

Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients.

Author information

1
*Medical Technology and Practice Patterns Institute (MTPPI), Bethesda, MD †VA NY Harbor Healthcare System, New York, NY Departments of ‡Epidemiology §Biostatistics, Harvard School of Public Health ∥Harvard-MIT Division of Health Sciences and Technology, Boston, MA.

Abstract

BACKGROUND:

Randomized trials found that use of erythropoiesis-stimulating agents to target normal hematocrit (Hct) levels (>39%) compared with 27%-34.5% increases cardiovascular risk and mortality among chronic kidney disease patients. However, the effects of the most widely used Hct target in the past 2 decades, 34.5%-39%, have never been examined.

OBJECTIVE:

To compare the effects of 2 Hct target strategies-30.0%-34.5% (low) and 34.5%-39.0% (mid) in a high-risk population: elderly dialysis patients with significant comorbidities.

RESEARCH DESIGN:

Observational data from the US Renal Data System were used to emulate a randomized trial in which patients were assigned to either Hct strategy. Follow-up started after completing 3 months of hemodialysis and ended 6 months later. We conducted the observational analogs of intention-to-treat and per-protocol analyses. Inverse-probability weighting was used to adjust for measured time-dependent confounding by indication.

SUBJECTS:

A total of 22,474 elderly patients with both diabetes and cardiovascular disease who initiated hemodialysis in 2006-2008.

MEASURES:

Hazard ratios (HRs) and survival probabilities for all-cause mortality and a composite cardiovascular and mortality endpoint.

RESULTS:

The intention-to-treat HR (95% confidence interval) for mid versus low Hct strategy was 1.05 (0.99-1.11) for all-cause mortality and 1.03 (0.98-1.08) for the composite endpoint. The per-protocol HR (95% confidence interval) for mid versus low Hct strategy was 0.98 (0.78-1.24) for all-cause mortality and 1.00 (0.81-1.24) for the composite outcome.

CONCLUSIONS:

Among hemodialysis patients, we did not find differences in 6-month survival or cardiovascular risk between clinical strategies that target Hct at 30.0%-34.5% versus 34.5%-39.0%.

PMID:
24561752
PMCID:
PMC3933821
DOI:
10.1097/MLR.0b013e3182a53ca8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center